Non-Hodgkin's Lymphoma, Phase I-II
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
Volunteers
Health Professionals
What is the purpose of this trial?
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alfredo Axtmayer
- Amer Zeidan, MBBS
- Elan Gorshein, DO, JD, MPH
- Francine Foss, MD
- Jean Vollmer
- Kaitlin Brown
- Lourdes Mendez, MD, PhD
- Natalia Neparidze, MD
- Nikolai Podoltsev, MD, PhD
- Rory Shallis, MD
- Sabrina Browning, MD
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stephanie Halene, MD, Dr Med
- Stuart Seropian, MD
- Tarsheen Sethi, MD, MSc
- Terri Parker, MD
- Last Updated04/12/2024
- Study HIC#2000032574